Biblio

13 resultats trouvés
Filtres: Auteur is Escudier, B.  [Clear All Filters]
A
Derosa L., C. Silva ACosta, Dalban C., Colomba E., Negrier S., Chevreau C.M, Gravis G., Oudard S.M, Laguerre B., Barthelemy P. et al..  2021.  Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study. ANNALS OF ONCOLOGY. 32:S681.
B
Oudard S., Mejean A., Topart D., Thuret R., Tournigand C., Salomon L., Thiery-Vuillemin A., Guichard G., Le Moulec S., Houlgatte A. et al..  2017.  Biomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium). ANNALS OF ONCOLOGY. 28
Oudard S., Mejean A., Topart D., Thuret R., Tournigand C., Salomon L., Thiery-Vuillemin A., Guichard G., Le Moulec S., Houlgatte A. et al..  2017.  Biomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium). ANNALS OF ONCOLOGY. 28
Flippot R., Dalban C., Laguerre B., Borchiellini D., Gravis G., Negrier S., Chevreau C.M, Joly F., Geoffrois L., Ladoire S. et al..  2018.  Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial. ANNALS OF ONCOLOGY. 29:306.
Flippot R., Dalban C., Laguerre B., Borchiellini D., Gravis G., Negrier S., Chevreau C.M, Joly F., Geoffrois L., Ladoire S. et al..  2018.  Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial. ANNALS OF ONCOLOGY. 29:306.
C
Gross-Goupil M., Flechon A., Mourey L., Topart D., Gravis G., Oudard S., Tourani J.M, Geoffrois L., Meriaux E., Thiery-Vuillemin A. et al..  2020.  Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study. ANNALS OF ONCOLOGY. 31:S566-S567.
Flechon A., Chevreau C.M, Topart D., Gravis G., Oudard S., Tourani J.M, Geoffrois L., Meriaux E., Thiery-Vuillemin A., Barthelemy P. et al..  2020.  Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study. ANNALS OF ONCOLOGY. 31:S572-S573.
F
Ravaud A., Oudard S., De Fromont M., Chevreau C., Gravis G., Zanetta S., Theodore C., Jimenez M., Sevin E., Laguerre B. et al..  2015.  First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). ANNALS OF ONCOLOGY. 26:1123-1128.
G
Kramar A., Negrier S., Sylvester R., Joniau S., Mulders P., Powles T., Bex A., Bonnetain F., Bossi A., Bracarda S. et al..  2015.  Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project(aEuro). ANNALS OF ONCOLOGY. 26:2392-2398.
I
Lefort F., Dalban C., Gross-Goupil M., Laguerre B., Barthelemy P., Sarradin V., Chanez B., Negrier S., Geoffrois L., Gillon P. et al..  2019.  Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma. ANNALS OF ONCOLOGY. 30:391.
P
Courcier J., Dalban C., Laguerre B., Ladoire S., Barthelemy P., Oudard S., Joly F., G. Mescam G, Chevreau C.M, Geoffrois L. et al..  2020.  Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial. ANNALS OF ONCOLOGY. 31:S560.
S
Mejean A., Ravaud A., Thezenas S., Colas S., Beauval J.-B, Bensalah K., Geoffrois L., Thiery-Vuillemin A., Cormier L., Lang H. et al..  2018.  Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE. 379:417-427.
W
Thiery-Vuillemin A., Albiges L., Escudier B., Narciso B., Bigot P., Eymard J-C., Calcagno F., Schlurmann F., Chehimi M., Barthomeuf J. et al..  2021.  WITNESS: Real-world outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with nivolumab in France and subgroup analysis of patients receiving concomitant medications at baseline. ANNALS OF ONCOLOGY. 32:S697.